XHKG
2235
Market cap368mUSD
Oct 07, Last price
6.99HKD
1D
0.58%
1Q
-2.24%
IPO
-77.08%
Name
MicroTech Medical Hangzhou Co Ltd
Chart & performance
P/E
61.37
P/S
3.73
EPS
0.10
Div yield, %
—
Shrs. gr., 5y
-1.06%
Rev. gr., 5y
54.41%
Revenues
661m
+91.19%
Net income
40m
P
CFO
32m
P
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
MicroTech Medical (Hangzhou) Co., Ltd. focuses on the innovation, production, and market distribution of essential medical devices and consumables for diabetes management. Its operations extend across the People's Republic of China and into global markets. The company offers a comprehensive range of products, including the Equil Patch insulin pump systems, AiDEX continuous glucose monitoring systems, POCT analyzer systems, traditional blood glucose monitoring systems, and advanced closed-loop artificial pancreas technology. Beyond its core offerings, MicroTech Medical is also actively involved in engineering and technological research, experimentation, and developmental endeavors. The firm, established in 2011, maintains its headquarters in Hangzhou, People's Republic of China.
Key people
Xiu Liu
Executive Director
Fei Yu
Executive Director
Pan Zheng
Chairman of the Board, Executive Director
Joint Company Secretary · since 2023
Yonghui Shi
Senior Vice President, Executive Director, Secretary of the Board, Joint Company Secretary · since 2024
Yun Gao
Non-Executive Director
Shuo Mao
Non-Executive Director · since 2023
Hua Cheng
Non-Executive Independent Director · since 2022
Kin Cheong Ho
Independent Non-Executive Director
Lihua Li
Independent Non-Executive Director
Chunfeng Wang
Independent Non-Executive Director
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||||
Revenues | |||||||
Cost of revenue | |||||||
Unusual Expense (Income) | |||||||
NOPBT | |||||||
NOPBT Margin | |||||||
Operating Taxes | |||||||
Tax Rate | |||||||
NOPAT | |||||||
Net income | |||||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | |||||||
BB yield | |||||||
| Debt | |||||||
Debt current | |||||||
Long-term debt | |||||||
Deferred revenue | |||||||
Other long-term liabilities | |||||||
Net debt | |||||||
| Cash flow | |||||||
Cash from operating activities | |||||||
CAPEX | |||||||
Cash from investing activities | |||||||
Cash from financing activities | |||||||
FCF | |||||||
| Balance | |||||||
Cash | |||||||
Long term investments | |||||||
Excess cash | |||||||
Stockholders' equity | |||||||
Invested Capital | |||||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | |||||||
Price | |||||||
Market cap | |||||||
EV | |||||||
EBITDA | |||||||
EV/EBITDA | |||||||
Interest | |||||||
Interest/NOPBT | |||||||